author_facet Ryder, REJ
Ryder, REJ
author Ryder, REJ
spellingShingle Ryder, REJ
Practical Diabetes International
Rosiglitazone versus pioglitazone in relation to cardiovascular disease in type 2 diabetes: primum non nocere
Endocrinology, Diabetes and Metabolism
Internal Medicine
author_sort ryder, rej
spelling Ryder, REJ 1357-8170 1528-252X Wiley Endocrinology, Diabetes and Metabolism Internal Medicine http://dx.doi.org/10.1002/pdi.1168 Rosiglitazone <i>versus</i> pioglitazone in relation to cardiovascular disease in type 2 diabetes: <i>primum non nocere</i> Practical Diabetes International
doi_str_mv 10.1002/pdi.1168
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9wZGkuMTE2OA
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9wZGkuMTE2OA
institution DE-Zwi2
DE-D161
DE-Zi4
DE-Gla1
DE-15
DE-Pl11
DE-Rs1
DE-14
DE-105
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
imprint Wiley, 2007
imprint_str_mv Wiley, 2007
issn 1357-8170
1528-252X
issn_str_mv 1357-8170
1528-252X
language English
mega_collection Wiley (CrossRef)
match_str ryder2007rosiglitazoneversuspioglitazoneinrelationtocardiovasculardiseaseintype2diabetesprimumnonnocere
publishDateSort 2007
publisher Wiley
recordtype ai
record_format ai
series Practical Diabetes International
source_id 49
title Rosiglitazone versus pioglitazone in relation to cardiovascular disease in type 2 diabetes: primum non nocere
title_unstemmed Rosiglitazone versus pioglitazone in relation to cardiovascular disease in type 2 diabetes: primum non nocere
title_full Rosiglitazone versus pioglitazone in relation to cardiovascular disease in type 2 diabetes: primum non nocere
title_fullStr Rosiglitazone versus pioglitazone in relation to cardiovascular disease in type 2 diabetes: primum non nocere
title_full_unstemmed Rosiglitazone versus pioglitazone in relation to cardiovascular disease in type 2 diabetes: primum non nocere
title_short Rosiglitazone versus pioglitazone in relation to cardiovascular disease in type 2 diabetes: primum non nocere
title_sort rosiglitazone <i>versus</i> pioglitazone in relation to cardiovascular disease in type 2 diabetes: <i>primum non nocere</i>
topic Endocrinology, Diabetes and Metabolism
Internal Medicine
url http://dx.doi.org/10.1002/pdi.1168
publishDate 2007
physical 422-425
description
container_issue 8
container_start_page 422
container_title Practical Diabetes International
container_volume 24
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792338357066399746
geogr_code not assigned
last_indexed 2024-03-01T15:30:56.616Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Rosiglitazone+versus+pioglitazone+in+relation+to+cardiovascular+disease+in+type+2+diabetes%3A+primum+non+nocere&rft.date=2007-10-01&genre=article&issn=1528-252X&volume=24&issue=8&spage=422&epage=425&pages=422-425&jtitle=Practical+Diabetes+International&atitle=Rosiglitazone+%3Ci%3Eversus%3C%2Fi%3E+pioglitazone+in+relation+to+cardiovascular+disease+in+type+2+diabetes%3A+%3Ci%3Eprimum+non+nocere%3C%2Fi%3E&aulast=Ryder&aufirst=REJ&rft_id=info%3Adoi%2F10.1002%2Fpdi.1168&rft.language%5B0%5D=eng
SOLR
_version_ 1792338357066399746
author Ryder, REJ
author_facet Ryder, REJ, Ryder, REJ
author_sort ryder, rej
container_issue 8
container_start_page 422
container_title Practical Diabetes International
container_volume 24
description
doi_str_mv 10.1002/pdi.1168
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9wZGkuMTE2OA
imprint Wiley, 2007
imprint_str_mv Wiley, 2007
institution DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1
issn 1357-8170, 1528-252X
issn_str_mv 1357-8170, 1528-252X
language English
last_indexed 2024-03-01T15:30:56.616Z
match_str ryder2007rosiglitazoneversuspioglitazoneinrelationtocardiovasculardiseaseintype2diabetesprimumnonnocere
mega_collection Wiley (CrossRef)
physical 422-425
publishDate 2007
publishDateSort 2007
publisher Wiley
record_format ai
recordtype ai
series Practical Diabetes International
source_id 49
spelling Ryder, REJ 1357-8170 1528-252X Wiley Endocrinology, Diabetes and Metabolism Internal Medicine http://dx.doi.org/10.1002/pdi.1168 Rosiglitazone <i>versus</i> pioglitazone in relation to cardiovascular disease in type 2 diabetes: <i>primum non nocere</i> Practical Diabetes International
spellingShingle Ryder, REJ, Practical Diabetes International, Rosiglitazone versus pioglitazone in relation to cardiovascular disease in type 2 diabetes: primum non nocere, Endocrinology, Diabetes and Metabolism, Internal Medicine
title Rosiglitazone versus pioglitazone in relation to cardiovascular disease in type 2 diabetes: primum non nocere
title_full Rosiglitazone versus pioglitazone in relation to cardiovascular disease in type 2 diabetes: primum non nocere
title_fullStr Rosiglitazone versus pioglitazone in relation to cardiovascular disease in type 2 diabetes: primum non nocere
title_full_unstemmed Rosiglitazone versus pioglitazone in relation to cardiovascular disease in type 2 diabetes: primum non nocere
title_short Rosiglitazone versus pioglitazone in relation to cardiovascular disease in type 2 diabetes: primum non nocere
title_sort rosiglitazone <i>versus</i> pioglitazone in relation to cardiovascular disease in type 2 diabetes: <i>primum non nocere</i>
title_unstemmed Rosiglitazone versus pioglitazone in relation to cardiovascular disease in type 2 diabetes: primum non nocere
topic Endocrinology, Diabetes and Metabolism, Internal Medicine
url http://dx.doi.org/10.1002/pdi.1168